Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | CA4 | P22748 | 2/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.44 |
| ▸ | PTGFR | P43088 | 2/20 | 0.44 |
| ▸ | PTGIR | P43119 | 2/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | ITGAL | P20701 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 7/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2477599 | 1.00 | CA1 (0.48) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL28200281 | 0.86 | PTGER3 (0.51) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL15053650 | 0.82 | PTGER3 (0.45) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL15053649 | 0.82 | PTGER3 (0.45) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL29110172 | 0.79 | ALDH1A1 (0.55) | CA1CA2MAPTDPP4HSD17B10 | |
| SCHEMBL8942468 | 0.78 | MIF (0.53) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL8849999 | 0.78 | MIF (0.53) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL9251180 | 0.78 | HSD17B10 (0.41) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL9251177 | 0.78 | HSD17B10 (0.41) | CA1CA2NFKB1CA4PTGER3 | |
| SCHEMBL8849971 | 0.77 | MIF (0.51) | CA1CA2NFKB1CA4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111943900-B | Isoxazoline derivatives and their use in agriculture | 宁夏苏融达化工有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-111943900-A | Isoxazoline derivatives and their use in agriculture | 东莞市东阳光农药研发有限公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-2794576-A1 | NON-SYSTEMIC TGR5 AGONISTS | Ardelyx, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096771-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| EP-2370438-A1 | IMIDAZO [1,2A]PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | Exelixis, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | CA1 3941/4885CA2 3515/4885NFKB1 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.